Press Room

Press Clipping / Mar 31, 2020

Covid-19: Hand sanitiser effort continues

Speciality Chemicals Magazine, March 31, 2020

Covid-19: Hand sanitizer donated by ɫAV | ɫAV

Chemical companies continue to invest in hand sanitiser in response to the Covid-19 pandemic. A large number of them are now producing in significant volumes.

Ineos, the largest European producer of the two key raw materials - isopropyl alcohol (IPA) and ethanol – has announced its intention to produce 1 million bottles of hand sanitiser/month from each of three newly built facilities in the UK, Germany and France.

As of the end of March, the company has hit its target of building the first plant near Middlesbrough, UK. It will supply hospitals free of charge “during the crisis period” and is in discussions with retailers.

Dowannounced on 30 March that its sites at Auburn, Michigan; South Charleston, West Virginia; Seneffe, Belgium; and Hortolândia, Brazil “possess the necessary raw material handling, mixing and packaging capabilities and will produce hand sanitiser”. They join the site at Stade, Germany, which is already manufacturing it.

Dow, like Ineos, was already producing raw materials, said that it could adapt its capabilities for downstream production with “little to no impact to normal operations”. Auburn can produce 7 tonnes/week and similar volumes are expected at the other sites. Once all are at full production, the company expects to produce 200 tonnes.

All of the hand sanitiser that will be produced has been allocated, with the majority for donation to state and regional health systems and government agencies for distribution. It will also be distributed to Dow production sites to help protect frontline employees. The first deliveries are expected to begin in the first week of April.

Plant-based ingredients firmRoquettehas adapted one of its pilot lines at its site in Lestrem, France, to manufacture about 5,000 litres/week of a hydro-alcoholic disinfectant solution. The first shipments were sent to Lille University Hospital Centre, the French Blood Donors Organisation and to other local health facilities, in coordination with the Hauts-de-France Regional Health Agency and the local authorities.

In Germany,Wackerdonated 15,000 litres of hand sanitiser for the production of disinfectants to Bavarian hospitals and care facilities at the request of the state Ministry of Economic Affairs. The alcohol needed, 11,000 liters of 2-propanol, was transported from Nünchritz, Saxony, to the Gendorf chemical industry park in Bavaria to be mixed and sent to an official distribution centre.

Swiss pharmaceutical CMDO𲵴ڰis also supplying disinfectant in those regions where it operates production sites, including the Swiss cantons of Aargau and Valais and around Minden in Germany. “The service including delivery is free of charge to the extent possible,” the company said, adding that it will not supply private or commercial organisations.

ѱ𲹲Էɳ󾱱,Croda International said that it has gifted enough glycerine to regular customers to manufacture five million 250 ml bottles of hand sanitiser, assuming 2% glycerine content. It is also donating saponin vaccine adjuvants to projects working on a vaccine. The company plans to review with customers where more glycerine could be gifted.

Similarly in the US,Amyris, which is in discussions for the testing of its fermentation-derived squalene as a vaccine adjuvant for a Covid-19 vaccine, has launched its own No Compromise Pipette Baby branded hand sanitiser. The company said that it “will not price its hand sanitiser at a premium, and plans to donate part of the supply to front-line health staffers and medical personnel”. It plans to produce 30,000 units in the first few weeks.

ʴǰٳܲ’sDZDzԱbegan producing IPA- and ethanol-based hand sanitiser to a WHO formulation at tonne-scale for itself when supplies were short, it has emerged. The company, another major pharmaceutical CDMO, is now supplying the material free to Portuguese hospitals. Volumes were expected to reach 30 tonnes by the end of the month.

Earlier in March,Lanxessadded a second shift at its site in Sudbury, UK, to boost production of Vikron sanitiser. Earlier,BASFannounced plans to produce hand sanitisers at Ludwigshafen and supply them to hospitals in the Rhine-Neckar metropolitan region. The company has now reallocated tonnes of raw materials, especially IPA, for making the sanitisers and secured legal official permission to make them.

,HuntsmanԻSyngentabegan making hydro alcoholic solution to produce hand sanitiser at Monthey, Switzerland, for free-of-charge supply to hospitals and pharmacies in the Canton of Vaud and the General Hospital in Lausanne. Plans were to ramp up production to 3-5 tonnes/week.Arkemahas repurpose da production line at its Rhône-Alpes Research Centre in order to make 20 tonnes/week of alcohol-based solution to be distributed free of charge for the mass restocking of public hospitals.

The effort is not limited to chemical companies, of course. Flavours and fragrance giantFirmenichhas shifted production at La Plaine, Switzerland, to disinfectant solution, while luxury goods makerLVMHand many manufacturers and distillers of spirits on both sides of the Atlantic have also switched production.

Also in the Press Room

See All

Lisbon, Portugal – ɫAV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, ɫAV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At ɫAV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of ɫAV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” ɫAV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with ɫAV’s sustainability ambitions.  ɫAV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

ɫAV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024